Rybelsus (oral semaglutide for diabetes)
Shrinking in Q2 2026 as Wegovy pill and Ozempic pricing pressure weigh on it.
The numbers
Adjusted salesDKK 5,228 millionQ2 2026 · -4% at constant exchange rates · source ↗
What it is
Daily oral semaglutide tablet for type 2 diabetes, the company's first oral GLP-1 for diabetes.
Why it matters to the stock. Rybelsus shows how much of the diabetes franchise is being reshaped by oral GLP-1s, which the Wegovy pill now competes with.
News
No stories tagged to this project yet.